Voltage-gated ion channel
Kv7.2/Kv7.3 (KCNQ2/3, M-channel)
Voltage-gated potassium channel, Kv7.2/Kv7.3 heteromer (M-current)
- GeneKCNQ2/KCNQ3
- FamilyVoltage-gated potassium channels
- GroupKv7 potassium channels
- TypeA defined subunit combination.
Kv7.2 and Kv7.3 subunits coassemble into a heteromeric channel whose kinetics, pharmacology and expression pattern are consistent with the native M-current. The KCNQ2 gene was identified in 1998 in a chromosome 20 deletion that co-segregated with seizures in a family with benign familial neonatal convulsions, a dominantly inherited epilepsy of newborns, and five other probands of such families had KCNQ2 mutations. Mutations in KCNQ3 can cause the same disorder.1,2,3 Gabapentin activates the Kv7.2/Kv7.3 heteromer in the nanomolar range, while the related gabapentinoid pregabalin does not activate it and inhibits it at higher concentrations.4
Sources (4)
- Wang et al. 1998Wang HS, Pan Z, Shi W, et al. (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel Science
- Singh et al. 1998Singh NA, Charlier C, Stauffer D, et al. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns Nat Genet
- Schroeder et al. 2000Schroeder BC, Hechenberger M, Weinreich F, et al. (2000) KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents J Biol Chem
- Manville et al. 2018Manville RW, Abbott GW (2018) Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels Mol Pharmacol
Functional potency (EC₅₀)
1 substance, 1 displayed value. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.
Human
1 measurement
Gabapentin4.2 nMManville et al. 2018
- Assay
- human KCNQ2/3 (Kv7.2/7.3) expressed in Xenopus oocytes, two-electrode voltage clamp, current activation
- Shown value from
- Manville et al. 2018, Results text
Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.